转位蛋白及其配体在神经精神疾病中作用
Study on TSPO and Ligand in the Psychiatry and Neurology Disease

DOI: 10.12677/IJPN.2019.82002, PP. 7-12

Keywords: 转位蛋白，配体，神经影像，神经精神疾病
TSPO, Ligand, Neuroimaging, Psychiatry and Neu-rology Disease

Full-Text   Cite this paper   Add to My Lib

Abstract:

转位蛋白(translocator protein, TSPO)是苯二氮卓类药物外周组织结合位点，又称外周型苯二氮卓受体(peripheral benzodiazepine receptor, PBR)。随着研究的深入，将PBR第一亚单位(即位于线粒体外膜的异喹啉结合点地西泮结合抑制物)重新命名为18kDa转位蛋白。TSPO及其配体在疾病中的重要作用成为近几年研究的热点。研究显示TSPO具有广泛的生理调节功能，参与了卒中、神经退行性病变、神经免疫病及神经精神疾病等多种疾病的发生发展，其配体作为生物标记物和治疗目标，在影像成像及炎症在体监测中扮演着重要的角色。然而，TSPO在神经系统疾病中精确作用仍然是个迷。本文将对TSPO及其配体在中枢神经系统中作用的最新研究进行综述。
TSPO is the peripheral tissue binding site of benzodiazepine drugs, also known as peripheral benzodiazepine receptor (PBR). With the further research, the first subunit of PBR (i.e. the isoquinoline binding site of diazepam binding inhibitor located in the outer membrane of mitochondria) was renamed as 18kDa translocation protein. The important role of TSPO and its ligands in diseases has become a hotspot in recent years. Studies have shown that TSPO has a wide range of physiological regulation functions, and is involved in the occurrence and development of stroke, neurodegenerative diseases, neuroimmune diseases, neuropsychiatric diseases and other diseases. As biomarkers and treatment targets, its ligands play an important role in imaging and inflammation monitoring. However, the precise role of TSPO in neurological disorders remains a mystery. This article will review the latest research on the role of TSPO and its ligands in the central nervous system.

References

[1]	Li, F., Liu, J., Liu, N., Kuhn, L.A., Garavito, R.M. and Ferguson-Miller, S. (2016) Translocator Protein 18 kDa (TSPO): An Old Protein with New Functions? Biochemistry, 55, 2821-2831. https://doi.org/10.1021/acs.biochem.6b00142
[2]	Batarseh, A. and Papadopdulos, V. (2010) Regulation of Translocator Protein 18 kDa (TSPO) Expression in Health and Disease States. Molecular and Cellular Endocrinology, 327, 1-12. https://doi.org/10.1016/j.mce.2010.06.013
[3]	Morin, D., Musman, J., Pons, S., Berdeaux, A. and Ghaleh, B. (2016) Mitochondrial Translocator Protein (TSPO): From Physiology to Cardioprotection. Biochemical Pharmacology, 105, 1-13. https://doi.org/10.1016/j.bcp.2015.12.003
[4]	Olga, V.C. and Wenbin, D. (2016) Mitochondrial Translocator Protein (TSPO), Astrocytes and neuroinflammation. Neural Regeneration Research, 11, 1056-1057. https://doi.org/10.4103/1673-5374.187027
[5]	Zhan, A.H., Tu, L.N., Mukai, C., Sirivelu, M.P., Pillai, V.V., Morohaku, K., Cohen, R. and Selvaraj, V. (2016) Mitochondrial Translocator Protein (TSPO) Function Is Not Essential for Heme Biosynthesis. The Journal of Biological Chemistry, 291, 1591-1603. https://doi.org/10.1074/jbc.M115.686360
[6]	Hamelin, L., Lagarde, J., Dorothee, G., et al. (2018) Distinct Dynamic Profiles of Microglial Activation Are Associated with Progression of Alzheimer’s Disease. Brain, 141, 1855-1870. https://doi.org/10.1093/brain/awy079
[7]	Jin, G.-L., He, S.-D., Lin, S.-M., et al. (2018) Koumine Attenuates Neuroglia Activation and Inflammatory Response to Neuropathic Pain. Neural Plasticity, 5, Article ID: 9347696. https://doi.org/10.1155/2018/9347696
[8]	Zeng, J., Guareschi, R., Damre, M., et al. (2018) Structural Prediction of the Dimeric Form of the Mammalian Translocator Membrane Protein TSPO: A Key Target for Brain Diagnostics. International Journal of Molecular Sciences, 19, 2588. https://doi.org/10.3390/ijms19092588
[9]	Coste, B., Dapozzo, E., Giacomelli, C., et al. (2016) TSPO Ligand Residence Time: A New Parameter to Predict Compound Neurosteroidogenic Efficacy. Scientific Reports, 6, Article No. 18164. https://doi.org/10.1038/srep18164
[10]	Verleye, M., Dumas, S., Heulard, I., et al. (2011) Differential Effects of Etifoxine on Anxiety-Like Behavior and Convulsions in BALB/cByJ and C57BL/6J Mice: Any Relation to Overexpression of Central GABAA Receptor Beta2 Subunits? European Neuropsychopharmacology, 21, 457-470. https://doi.org/10.1016/j.euroneuro.2010.09.008
[11]	Filiou, M.D., Banati, R.B. and Graeber, M.B. (2017) The 18-kDa Translocator Protein as a CNS Drug Target: Finding Our Way Through the Neuroinflammation Fog. CNS Neurological Disorders Drug Targets, 16, 990-999. https://doi.org/10.2174/1871527316666171004125107
[12]	Bonsack, F., Alleyne, C.H. and Sukumar, S. (2016) Augmented Expression of TSPO after Intracerebral Hemorrhage: A Role in Inflammation? Journal of Neuroinflammation, 13, 151. https://doi.org/10.1186/s12974-016-0619-2
[13]	Veiga, S., Azcoitia, I. and Garcia, L.M. (2005) Ro5-4864, a Peripheral Benzodiazepine Receptor Ligand, Reduces Reactive Gliosis and Protects Hippocampal Hilar Neurons from Kainic Acid Excitotoxicity. Journal of Neuroscience Research, 80, 129-137. https://doi.org/10.1002/jnr.20430
[14]	Leaver, K.R., Reynolds, A., Bodard, S., Guilloteau, D., Chalon, S. and Kassiou, M. (2012) Effects of Translocator Protein (18 kDa) Ligands on Microglial Activation and Neuronal Death in the Quinolinic-Acid-Injected Rat Striatum. ACS Chemical Neuroscience, 3, 114-119. https://doi.org/10.1021/cn200099e
[15]	Gong, J., Szeg？, é.M., Leonov, A., et al. (2019) Translocator Protein Ligand Protects against Neurodegeneration in the MPTP Mouse Model of Parkinsonism. Journal of Neuroscience, 2, 2070-2018. https://doi.org/10.1523/JNEUROSCI.2070-18.2019
[16]	Lenglet, T., Lacomblez, L., Abitbol, J.L., et al. (2014) A Phase II-III Trial of Olesoxime in Subjects with Amyotrophic Lateral Sclerosis. European Journal of Neurology, 21, 529-536. https://doi.org/10.1111/ene.12344
[17]	Kapanadze, T., Bankstahl, J.P., Wittneben, A., et al. (2019) Multimodal and Multiscale Analysis Reveals Distinct Vascular, Metabolic and Inflammatory Components of the Tissue Response to Limb Ischemia. Theranostics, 9, 152-166. https://doi.org/10.7150/thno.27175
[18]	Locci, A. and Pinna, G. (2017) Neurosteroid Biosynthesis Down-Regulation and Changes in GABAA Receptor Subunit Composition: A Biomarker Axis in Stress-Induced Cognitive and Emotional Impairment. British Journal of Pharmacology, 174, 3226-3241. https://doi.org/10.1111/bph.13843
[19]	Nothdurfter, C., Baghai, T.C., Schüle, C. and Rupprecht, R. (2012) Translocator Protein (18 kDa) (TSPO) as a Therapeutic Target for Anxiety and Neurologic Disorders. European Archives of Psychiatry and Clinical Neuroscience, 262, S107-S12. https://doi.org/10.1007/s00406-012-0352-5
[20]	Poisbeau, P., Gazzo, G. and Calvel, L. (2018) Anxiolytics Targeting GABAA Receptors: Insights on Etifoxine. The World Journal of Biological Psychiatry, 19, S36-S45. https://doi.org/10.1080/15622975.2018.1468030
[21]	Li, X.-B., Liu, A., Yang, L., et al. (2018) Antidepressant-Like Effects of Translocator Protein (18 kDa) Ligand ZBD-2 in Mouse Models of Postpartum Depression. Molecular Brain, 11, 1-12. https://doi.org/10.1186/s13041-018-0355-x
[22]	Zhang, L.-M., Qiu, Z.-K., Zhao, N., et al. (2014) Anxiolytic-Like Effects of YL-IPA08, a Potent Ligand for the Translocator Protein (18 kDa) in Animal Models of Post-Traumatic Stress Disorder. International Journal of Neuropsychopharmacology, 17, 1659-1669. https://doi.org/10.1017/S1461145714000479
[23]	Luo, L.-F., Weng, J.-F., Cen, M., et al. (2019) Prognostic Significance of Serum Translocator Protein in Patients with Traumatic Brain Injury. Clinica Chimica Acta, 488, 25-30. https://doi.org/10.1016/j.cca.2018.10.035
[24]	Palzur, E., Sharon, A., Shehadeh, M. and Soustiel, J.F. (2016) Investigation of the Mechanisms of Neuroprotection Mediated by Ro5-4864 in Brain Injury. Neuroscience, 329, 162-170. https://doi.org/10.1016/j.neuroscience.2016.05.014
[25]	Li, X.-M., Meng, J., Li, L.-T., et al. (2017) Effect of ZBD-2 on Chronic Pain, Depressive-Like Behaviors, and Recovery of Motor Function Following Spinal Cord Injury in Mice. Behavioural Brain Research, 30, 92-99. https://doi.org/10.1016/j.bbr.2017.01.025
[26]	Pigeon, H., Pérès, E.A., Truillet, C., et al. (2019) TSPO-PET and Diffusion-Weighted MRI for Imaging a Mouse Model of Infiltrative Human Glioma. Neuro-Oncology, 2, noz029. https://doi.org/10.1093/neuonc/noz029
[27]	Zeno, S., Zaaroor, M., Leschiner, S., Veenman, L. and Gavish, M. (2009) CoCl2 Induces Apoptosis via the 18 kDa Translocator Protein in U118MG Human Glioblastoma Cells. Biochemistry, 48, 4652-4661. https://doi.org/10.1021/bi900064t
[28]	Daugherty, D.J., Selvaraj, V., Chechneva, O.V., et al. (2013) A TSPO Ligand Is Protective in a Mouse Model of Multiple Sclerosis. EMBO Molecular Medicine, 5, 891-903. https://doi.org/10.1002/emmm.201202124
[29]	Abid, K.A., Sobowale, O.A., Parkes, L.M., et al. (2018) Assessing Inflammation in Acute Intracerebral Hemorrhage with PK11195 PET and Dynamic Contrast-Enhanced MRI. Journal of Neuroimaging, 28, 158-161. https://doi.org/10.1111/jon.12477

Full-Text